Journal
ACS NANO
Volume 11, Issue 12, Pages 12276-12291Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsnano.7b05966
Keywords
near-infrared window II; photoacoustic imaging; donor-acceptor chromophore; epidermal growth factor receptor; thyroid carcinoma
Categories
Funding
- Office of Science (BER), U.S. Department of Energy [DE-SC0008397]
- International S&T Cooperation Program of China [2015DFA30440]
- National Natural Science Foundation of China [81301268, 61601019]
- Beijing Nova Program [Z131107000413063]
- Beijing Natural Science Foundation [7164270]
- Fundamental Research Funds for Central Universities [2017RC025]
Ask authors/readers for more resources
Our development of multifunctional dual-modal imaging probes aims to integrate the benefits from both second near-infrared (NIR-II) fluorescence (1000-1700 nm) and photoacoustic imaging with an ultimate goal of improving overall cancer diagnosis efficacy. Herein we designed a donor acceptor chromophore based nanoparticle (DAP) as a dual-modal image contrast agent has strong absorption in the NIR-I window and a strong fluorescence emission peak in the NIR-II region. The dual-modal DAPs composed of D-pi-A-pi-D-type chromophores were PEGylated through nanoprecipitation. The multifunctional DAP surface was thus available for subsequent bioconjugation of EGFR Affibody (Ac-Cys-Z(EGER:1907)) to target EGFR-positive cancers. The Affibody-conjugated DAPS appeared as highly monodisperse nanoparticles (similar to 30 nm) with strong absorption in the MR-I window (at ca. 680 nm) and an extremely high fluorescence in the MR-II region (maximum peak at 1000 nm). Consequently, the Affibody-DAPs show significantly enhanced photoacoustic and MR-II fluorescence contrast effects in both in vitro and in vivo experiments. Moreover, the Affibody DAPs have the capability to selectively target EGFR-positive tumors in an FTC-133 subcutaneous mouse model with relatively high photoacoustic and fluorescent signals. By taking advantage of high spatial resolution and excellent temporal resolution, photoacoustic/NIR-II fluorescence imaging with targeted dual-modal contrast agents allows us to specifically image and detect various cancers and diseases in an accurate manner.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available